[
  {
    "ts": null,
    "headline": "Best Way To Invest $100,000: Build An 8-Stock Portfolio For Growth And Value",
    "summary": "Learn how to maximize returns by focusing on high-conviction stocks across diverse sectors and using proven investment strategies.",
    "url": "https://finnhub.io/api/news?id=55d1529df95faa211f30c69c3af5c9bc27914aaccba3736ed4c24b15134a2681",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734134056,
      "headline": "Best Way To Invest $100,000: Build An 8-Stock Portfolio For Growth And Value",
      "id": 131977467,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1445810162/image_1445810162.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Learn how to maximize returns by focusing on high-conviction stocks across diverse sectors and using proven investment strategies.",
      "url": "https://finnhub.io/api/news?id=55d1529df95faa211f30c69c3af5c9bc27914aaccba3736ed4c24b15134a2681"
    }
  },
  {
    "ts": null,
    "headline": "J&J Accuses Big Health Insurer of Helping Drain Its Drug Copay Funds",
    "summary": "Pharmaceutical company claims Cigna units worked with SaveOn and caused J&J to pay more than $100 million in copay assistance than it would have otherwise.",
    "url": "https://finnhub.io/api/news?id=4ff4d95af38d9ffa228914ea740a9dc9073a2bdd704292f9635af8ecec93aaa6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734123300,
      "headline": "J&J Accuses Big Health Insurer of Helping Drain Its Drug Copay Funds",
      "id": 131972564,
      "image": "",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Pharmaceutical company claims Cigna units worked with SaveOn and caused J&J to pay more than $100 million in copay assistance than it would have otherwise.",
      "url": "https://finnhub.io/api/news?id=4ff4d95af38d9ffa228914ea740a9dc9073a2bdd704292f9635af8ecec93aaa6"
    }
  },
  {
    "ts": null,
    "headline": "Imerys - Mining Value",
    "summary": "Imerys S.A. has struggled with subdued industrial demand but shows signs of recovery with an 11% one-year return. Learn more about IMYSF stock here.",
    "url": "https://finnhub.io/api/news?id=133b8488bf6ca0a8528c1591bde5e3b2a5a49f387ccc15064f957c8fe6cdf299",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734110547,
      "headline": "Imerys - Mining Value",
      "id": 131972919,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1443660378/image_1443660378.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Imerys S.A. has struggled with subdued industrial demand but shows signs of recovery with an 11% one-year return. Learn more about IMYSF stock here.",
      "url": "https://finnhub.io/api/news?id=133b8488bf6ca0a8528c1591bde5e3b2a5a49f387ccc15064f957c8fe6cdf299"
    }
  },
  {
    "ts": null,
    "headline": "Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report",
    "summary": "The Institute for Clinical and Economic Review (ICER) has identified five prescription drugs whose price increases in 2023 lacked sufficient clinical evidence to justify the hikes. Gilead Sciences Inc's (NASDAQ:GILD) Biktarvy, Johnson & Johnson's (NYSE:JNJ) Darzalex, Novartis AG's (NYSE:NVS) Entresto, Exelixis Inc (NASDAQ:EXEL) Cabometyx, and Pfizer Inc's (NYSE:PFE) Xeljanz are among the five drugs flagged for unsupported price increases. These five drugs' unsupported net price increases produce",
    "url": "https://finnhub.io/api/news?id=d28d4693d9b26aba0c475cf9417d5765371c0188a847ccf03da3198915d64a0d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734110107,
      "headline": "Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report",
      "id": 131969673,
      "image": "https://media.zenfs.com/en/Benzinga/a1f6fcbf33264a5c95130e307843f218",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The Institute for Clinical and Economic Review (ICER) has identified five prescription drugs whose price increases in 2023 lacked sufficient clinical evidence to justify the hikes. Gilead Sciences Inc's (NASDAQ:GILD) Biktarvy, Johnson & Johnson's (NYSE:JNJ) Darzalex, Novartis AG's (NYSE:NVS) Entresto, Exelixis Inc (NASDAQ:EXEL) Cabometyx, and Pfizer Inc's (NYSE:PFE) Xeljanz are among the five drugs flagged for unsupported price increases. These five drugs' unsupported net price increases produce",
      "url": "https://finnhub.io/api/news?id=d28d4693d9b26aba0c475cf9417d5765371c0188a847ccf03da3198915d64a0d"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson stock outperforms competitors on strong trading day",
    "summary": "Johnson & Johnson stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=d48c29c8def5da47322dfa616a8fbf329e50011caa6f17c4d2d28fb4c8500b52",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734107460,
      "headline": "Johnson & Johnson stock outperforms competitors on strong trading day",
      "id": 132064826,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Johnson & Johnson stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=d48c29c8def5da47322dfa616a8fbf329e50011caa6f17c4d2d28fb4c8500b52"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finnhub.io/api/news?id=633963918aec85c639a59a03b8c63f4ee64ec5cc1d376c78d29f9b550ed99fc2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734098417,
      "headline": "Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 131969674,
      "image": "https://media.zenfs.com/en/zacks.com/3496571a811465d910e99bd171c71a94",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.",
      "url": "https://finnhub.io/api/news?id=633963918aec85c639a59a03b8c63f4ee64ec5cc1d376c78d29f9b550ed99fc2"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson's (NYSE:JNJ) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?",
    "summary": "With its stock down 12% over the past three months, it is easy to disregard Johnson & Johnson (NYSE:JNJ). However...",
    "url": "https://finnhub.io/api/news?id=1f774170a608749f0c3ae17b2555ea571cc49d627265cc46ba7e2bfe45583434",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734094834,
      "headline": "Johnson & Johnson's (NYSE:JNJ) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?",
      "id": 131969675,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/2eedc463aef15274c4887c130e30e298",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "With its stock down 12% over the past three months, it is easy to disregard Johnson & Johnson (NYSE:JNJ). However...",
      "url": "https://finnhub.io/api/news?id=1f774170a608749f0c3ae17b2555ea571cc49d627265cc46ba7e2bfe45583434"
    }
  },
  {
    "ts": null,
    "headline": "FDA grants PMA approval to J&J MedTech’s heart pumps for paediatric use",
    "summary": "The company has collaborated with ACTION to gather real-world data supporting the on-label use of heart pumps.",
    "url": "https://finnhub.io/api/news?id=53e087a783e9cf3bb15d8a18aab52df0f25e9a2d357c5eea7022df7724519d7e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734089667,
      "headline": "FDA grants PMA approval to J&J MedTech’s heart pumps for paediatric use",
      "id": 131969676,
      "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/23/2024/12/MDN-2-JnJImpella-Shutterstock_1297294918.jpg",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The company has collaborated with ACTION to gather real-world data supporting the on-label use of heart pumps.",
      "url": "https://finnhub.io/api/news?id=53e087a783e9cf3bb15d8a18aab52df0f25e9a2d357c5eea7022df7724519d7e"
    }
  }
]